BridgeBio's Attruby Outperforms Pfizer’s Vyndamax in Real-World Study
BridgeBio Pharma (BBIO) announced that its heart disease treatment, acoramidis (Attruby), outperformed Pfizer’s tafamidis (Vyndamax) in a real-world study. The results showed Attruby to be more effective than Vyndamax for treating transthyretin cardiac amyloidosis. This news follows the FDA's approval of Attruby in November 2024. The findings could position BridgeBio’s drug as a preferred treatment option, potentially impacting Pfizer’s market share and sales of Vyndamax. The real-world evidence adds credibility to clinical trial data previously reported by BridgeBio, reinforcing its competitive edge in the therapeutic space for rare cardiac conditions.
